Results 111 to 120 of about 1,939 (155)

Tecovirimat for smallpox infections

Drugs of Today, 2010
SIGA Technologies, Inc. is a small biotech company committed to developing novel products for the prevention and treatment of serious viral diseases, with an emphasis on products to combat outbreaks that could result from bioterrorism. With government support, SIGA has developed the necessary infrastructure to successfully advance new antiviral drugs ...
T C, Bolken, D E, Hruby
openaire   +2 more sources

Tecovirimat Treatment for Monkeypox Virus Keratouveitis

JAMA Ophthalmology, 2023
This case report describes tecovirimat treatment for a patient with monkeypox virus–related keratouveitis.
Luciana P S, Finamor, Denise, de Freitas, Gabriel, Andrade, Víctor D, Bergamasco, Laura, Cunha, Carolina, Lázari, Cristina, Muccioli   +6 more
openaire   +2 more sources

Tecovirimat

Reactions Weekly
  +8 more sources

Tecovirimat for the Treatment of Mpox

New England Journal of Medicine
Tecovirimat is approved for smallpox treatment under the Food and Drug Administration Animal Rule on the basis of efficacy in nonhuman primate models of mpox (previously known as monkeypox). However, the clinical efficacy of tecovirimat against human clade II mpox is unclear.In a phase 3, international, double-blind, randomized, placebo-controlled ...
Jason Zucker, William A. Fischer, Lu Zheng, Caitlyn McCarthy, Pooja T. Saha, Arzhang Cyrus Javan, Alex Greninger, Matthew M. Hamill, Kieron Leslie, Kristina M. Brooks, Jonathan Berardi, Davey Smith, Lara Hosey, Grace Aldrovandi, Kathie Ferbas, Cheryl Day, Rachel A. Bender Ignacio, Robert Bolan, Marshall J. Glesby, Raphael J. Landovitz, Anne F. Luetkemeyer, Juan Sierra Madero, Rajesh T. Gandhi, Sharon Nachman, Joe Eron, Judith S. Currier, Timothy Wilkin   +26 more
openaire   +2 more sources

Tecovirimat

Reactions Weekly, 2023
  +4 more sources

Tecovirimat: First Global Approval

Drugs, 2018
Tecovirimat (TPOXX®) is an orthopoxvirus-specific antiviral drug developed by SIGA Technologies in conjunction with the US Department of Health and Human Services' Biomedical Advances Research and Development Authority. It acts by inhibiting the activity of the orthopoxvirus VP37 envelope wrapping protein, thereby preventing the formation of egress ...
openaire   +2 more sources

Tecovirimat hepatotoxicity in a man with Mpox infection

Enfermedades infecciosas y microbiologia clinica (English ed.)
In the context of the global Mpox outbreak from 2022 to 2024, tecovirimat has been widely used for Mpox treatment, initially demonstrating good tolerance and low toxicity. However, recent studies suggest limited efficacy in reducing Mpox lesions.We present the first reported case of significant hepatocellular injury associated with tecovirimat in a ...
Diana, Ruiz-Cabrera, Francisco, Montoya, Joaquín, Sáez-Peñataro, José, Riera, Pablo Manuel, Vargas, Ester, López-Suñé, María, López-Pont, Marina, Martinez-Illán, Alba, Catala, Montse, Tuset, Irene, Fuertes, Xavier, Forns, Jose Luis, Blanco   +12 more
openaire   +2 more sources